Tags

Type your tag names separated by a space and hit enter

Effect of Valsartan on hospitalization: results from Val-HeFT.
J Card Fail. 2003 Jun; 9(3):164-71.JC

Abstract

BACKGROUND

Although current therapies have improved heart failure (HF) outcome, hospitalizations continue at high rates. The Valsartan Heart Failure Trial (Val-HeFT) showed that valsartan reduced the risk of first worsening HF hospitalization by 27.5% versus placebo (P <.001). This article analyzes all-cause and investigator-assessed HF hospitalization in Val-HeFT overall and in subgroups defined by preexisting HF therapy.

METHODS

Val-HeFT was a randomized, double-blind parallel-arm study in which HF patients (New York Heart Association class II-IV) received either valsartan (n = 2511, force-titrated to 160 mg twice daily) or placebo (n = 2499) in addition to prescribed HF therapy. Total and per patient-year investigator-assessed hospitalizations (all-cause or HF) were analyzed according to prescribed therapy at baseline (angiotensin-converting enzyme inhibitors [ACEI] and beta-blockers [BB]).

RESULTS

Hospitalization for worsening HF accounted for 35% of all hospitalizations. There were 2856 and 3106 total all-cause hospitalizations in the valsartan and placebo groups, respectively, an 8% reduction (P =.145). Valsartan significantly reduced the overall number of investigator-assessed HF hospitalizations (-22.4%, P =.002) and reduced HF hospitalizations in the combination therapy subgroups (significant for ACEI+/BB- P =.003 and ACEI-/BB- P =.028) except those receiving both ACEI and BB. The benefit of valsartan versus placebo was more pronounced in reducing the number of patients with recurrent HF hospitalization (-20.6%) than single hospitalizations (-8.7%).

CONCLUSIONS

Addition of valsartan to prescribed HF therapy demonstrated significant reductions in HF hospitalizations and was particularly beneficial in reducing recurrent HF hospitalization.

Authors+Show Affiliations

Department of Veterans' Affairs, Medical Center, Washington, DC 20422, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12815565

Citation

Carson, Peter, et al. "Effect of Valsartan On Hospitalization: Results From Val-HeFT." Journal of Cardiac Failure, vol. 9, no. 3, 2003, pp. 164-71.
Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail. 2003;9(3):164-71.
Carson, P., Tognoni, G., & Cohn, J. N. (2003). Effect of Valsartan on hospitalization: results from Val-HeFT. Journal of Cardiac Failure, 9(3), 164-71.
Carson P, Tognoni G, Cohn JN. Effect of Valsartan On Hospitalization: Results From Val-HeFT. J Card Fail. 2003;9(3):164-71. PubMed PMID: 12815565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Valsartan on hospitalization: results from Val-HeFT. AU - Carson,Peter, AU - Tognoni,Gianni, AU - Cohn,Jay N, PY - 2003/6/20/pubmed PY - 2003/10/8/medline PY - 2003/6/20/entrez SP - 164 EP - 71 JF - Journal of cardiac failure JO - J Card Fail VL - 9 IS - 3 N2 - BACKGROUND: Although current therapies have improved heart failure (HF) outcome, hospitalizations continue at high rates. The Valsartan Heart Failure Trial (Val-HeFT) showed that valsartan reduced the risk of first worsening HF hospitalization by 27.5% versus placebo (P <.001). This article analyzes all-cause and investigator-assessed HF hospitalization in Val-HeFT overall and in subgroups defined by preexisting HF therapy. METHODS: Val-HeFT was a randomized, double-blind parallel-arm study in which HF patients (New York Heart Association class II-IV) received either valsartan (n = 2511, force-titrated to 160 mg twice daily) or placebo (n = 2499) in addition to prescribed HF therapy. Total and per patient-year investigator-assessed hospitalizations (all-cause or HF) were analyzed according to prescribed therapy at baseline (angiotensin-converting enzyme inhibitors [ACEI] and beta-blockers [BB]). RESULTS: Hospitalization for worsening HF accounted for 35% of all hospitalizations. There were 2856 and 3106 total all-cause hospitalizations in the valsartan and placebo groups, respectively, an 8% reduction (P =.145). Valsartan significantly reduced the overall number of investigator-assessed HF hospitalizations (-22.4%, P =.002) and reduced HF hospitalizations in the combination therapy subgroups (significant for ACEI+/BB- P =.003 and ACEI-/BB- P =.028) except those receiving both ACEI and BB. The benefit of valsartan versus placebo was more pronounced in reducing the number of patients with recurrent HF hospitalization (-20.6%) than single hospitalizations (-8.7%). CONCLUSIONS: Addition of valsartan to prescribed HF therapy demonstrated significant reductions in HF hospitalizations and was particularly beneficial in reducing recurrent HF hospitalization. SN - 1071-9164 UR - https://www.unboundmedicine.com/medline/citation/12815565/Effect_of_Valsartan_on_hospitalization:_results_from_Val_HeFT_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1071916403000137 DB - PRIME DP - Unbound Medicine ER -